It's really not like that. This guy didn't initially invest in the traditional way that you or I would. While I'm not an expert in this area, from what I do understand, his cash was "private financing" and not all of which was ever intended to be a long term investment in the company. Depending on the terms, he could make a considerable profit from the conversion of his notes to common shares. Depending on the series and such. The shares he was just issued December 31 are Series C Preferred. His status limits him to selling a maximum of 1% of his shares in any 90 day period. The Meadows liquidation sale is over. Also, for anyone to accept this class of stock and the attached limitations in exchange for cash or services tells me that they do believe that the company has excellent long term upside potential. Next, you have to consider something I've stated over and over. Just yesterday I at least partially said it again. Roy meadows selling his shares, in and of itself, would not have created such a decline in pps without all of the other circumstances coming together the way they did. The slander attacks made by so many, and they weren't even out of the same camp, were mostly responsible. The delays to key milestones which resulted in an extension to the period of 'alternative reporting" status, the subsequent delay of bigger investors coming to the party (probably the single greatest cause) and a ding to the quarterly numbers resulting from the Canadian delay. When you go back and couple the lack of "proof" or validation of the investment for those who must have it to justify the investment, and the vicious slander attacks by competitors, capitalist goons and good old blood sucking day traders in on the attack for whatever they can get, well I think you just can't really be surprised at the results. Most of us knew what was going on but expected the achievement of those milestones to intervene several months before they apparently will, and Roy Meadows didn't just "dump" his shares or I promise you we would've seen the stock back under a penny practically overnight. To sum it up, we're sitting better than we've ever been as we await the latest and greatest announcements. Of course it would have been nice to have a crystal ball and hold off on the bulk of our stock purchasing until now, but if we had such a device we'd already be rich! LOL My guess is we're looking at a healthy share structure for a start up, and they are making great strides with the expansion of the distribution footprint. All of a sudden will come some international distribution arrangements on top of that and we'll be on our way.
You're beating a dead horse with that issue. We're in good
It's really not like that. This guy didn't initially invest in the traditional way that you or I would. While I'm not an expert in this area, from what I do understand, his cash was "private financing" and not all of which was ever intended to be a long term investment in the company. Depending on the terms, he could make a considerable profit from the conversion of his notes to common shares. Depending on the series and such. The shares he was just issued December 31 are Series C Preferred. His status limits him to selling a maximum of 1% of his shares in any 90 day period. The Meadows liquidation sale is over. Also, for anyone to accept this class of stock and the attached limitations in exchange for cash or services tells me that they do believe that the company has excellent long term upside potential. Next, you have to consider something I've stated over and over. Just yesterday I at least partially said it again. Roy meadows selling his shares, in and of itself, would not have created such a decline in pps without all of the other circumstances coming together the way they did. The slander attacks made by so many, and they weren't even out of the same camp, were mostly responsible. The delays to key milestones which resulted in an extension to the period of 'alternative reporting" status, the subsequent delay of bigger investors coming to the party (probably the single greatest cause) and a ding to the quarterly numbers resulting from the Canadian delay. When you go back and couple the lack of "proof" or validation of the investment for those who must have it to justify the investment, and the vicious slander attacks by competitors, capitalist goons and good old blood sucking day traders in on the attack for whatever they can get, well I think you just can't really be surprised at the results. Most of us knew what was going on but expected the achievement of those milestones to intervene several months before they apparently will, and Roy Meadows didn't just "dump" his shares or I promise you we would've seen the stock back under a penny practically overnight. To sum it up, we're sitting better than we've ever been as we await the latest and greatest announcements. Of course it would have been nice to have a crystal ball and hold off on the bulk of our stock purchasing until now, but if we had such a device we'd already be rich! LOL My guess is we're looking at a healthy share structure for a start up, and they are making great strides with the expansion of the distribution footprint. All of a sudden will come some international distribution arrangements on top of that and we'll be on our way.
Top 10 Most Recent News Articles
Metriport Eyes Major Step in Health Data Integration
Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...
Continue Reading
Foodcare Proves Effective in Reducing Blood Sugar Levels
A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...
Continue Reading
Chad Tucker's Sequel Explores Deep Spiritual Themes
An Honest Take: Faith, Growth, and Surrender A player in the world of spiritual growth literature has stepped up again, and it ain't holding back. Chad Tucker, a name perhaps familiar to folks following transformation tales soaked with faith, has released a beefy sequel to his first hit: The Lord in Us: If You Can Love an Enemy, You Can Love Anyone. Well, now he's back...
Continue Reading
EnGenius Names Experienced VP to Boost Sales Growth
A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...
Continue Reading
Andover Audio's FreePlay: Stereo Sound Goes Portable
If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...
Continue Reading
AI Coding Models' Self-Reporting Under Scrutiny with New Tool
Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....
Continue Reading
Piedmont Orthopedics Expands Care in Henry County
A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...
Continue Reading
WareSpace Expands Reach With $36.5M Acquisitions
WareSpace Makes Strategic Moves in Tight Markets In a bold gamble, WareSpace dropped $36.5 million to snag fresh industrial real estate in Miami Gardens, Florida, and South San Francisco, California. These aren't random picks, mind you. They're strategic grabs in markets where finding space ain't easier than winning the lottery. With more than 210 flexible units for small...
Continue Reading
Bud Ecosystem Debuts AIOS, Aims to Slash Costs
AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...
Continue Reading
EmpowHer Grants Propel Female-led Social Ventures Forward
Every now and then, you stumble upon a story that makes you take off your trading hat and put on your 'citizen of the world' one. The Boundless Futures Foundation is doing just that, pushing past the $1.5 million mark in grant funding to back female founders creating real scale impact. If this doesn't sound like a nonprofit turning the gears of change, I don't know what...
Continue ReadingTop 5 Most Recently Viewed Articles
Vera Therapeutics Unveils Groundbreaking Atacicept Findings
Vera Therapeutics dropped some heavy news back in 2024 about its Phase 2b ORIGIN trial of atacicept, a treatment for IgAN. Traders were buzzing—reduced protein levels and stabilized kidney function sounded like a golden ticket. But let’s be real; it ain't that simple. You could almost hear the desks whispering, 'Yeah, we’ve seen this before.' Atacicept: The Mixed...
Continue Reading
California Housing Market Update: Trends and Insights
California Housing Market Overview In recent months, California's housing market has exhibited shifts, with home sales showing signs of recovery. The state saw existing, single-family home sales totaling 264,260 in June, demonstrating a 4.0 percent increase from May. However, this figure is down slightly from last year's totals, indicating cautious optimism as the market...
Continue Reading
Results from Santhera Pharmaceuticals' Annual General Meeting
Santhera Pharmaceuticals Shares AGM Outcomes Santhera Pharmaceuticals has successfully concluded its Annual General Meeting (AGM), where shareholders overwhelmingly approved all the motions proposed by the Board of Directors. This significant event saw the participation representing 5,073,050 shares, accounting for 37.5% of the company’s total share capital. Annual...
Continue ReadingAccelerated Growth at Vanguard International Semiconductor
Vanguard International Semiconductor's Expansion Plans Vanguard International Semiconductor (VIS), an affiliate of Taiwan Semiconductor Manufacturing Co (NASDAQ: TSM), is on a fast track to establish a significant $7.8 billion 300-millimeter chip manufacturing plant in Singapore. This development comes in light of rising geopolitical tensions and a growing imperative for...
Continue Reading
Innovative Partnership Between Reborn Coffee and Otonomus Hotel
Otonomus Hotel and Reborn Coffee Join Forces for AI-Driven Hospitality Reborn Coffee Inc. (NASDAQ: REBN), a leader in specialty coffee, and Otonomus Hotel are thrilled to announce a unique partnership focusing on integrating advanced technology into the hospitality experience. This collaboration is designed to revolutionize how guests enjoy coffee, promising an exciting...
Continue Reading